1
|
Scheyer N, Frey S, Koumakis E, Guérin C, Desailloud R, Groussin L, Cariou B, Vergès B, Brunaud L, Mirallié E, Figueres L, Lasolle H. Chapter 3: Impact of primary hyperparathyroidism. ANNALES D'ENDOCRINOLOGIE 2025; 86:101692. [PMID: 39818288 DOI: 10.1016/j.ando.2025.101692] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/18/2025]
Abstract
At present, primary hyperparathyroidism is most often discovered in an asymptomatic patient, but can sometimes be revealed by a renal or bone complications. In all cases, a full work-up is recommended, with assessment of renal function (glomerular filtration rate), 24-hour calciuria, screening for risk factors for lithiasis, and renal and urinary tract imaging (ultrasound or CT scan) to look for stones or nephrocalcinosis. Bone densitometry, with measurements of the spine, femur and radius, is the recommended reference test for demineralization. Standard X-rays of the spine or other imaging techniques are recommended for the detection of asymptomatic vertebral fracture. Neurocognitive manifestations, reduced quality of life or cardiovascular manifestations should not be routinely screened for, as they are not currently consensual criteria for surgical indications.
Collapse
Affiliation(s)
- Nicolas Scheyer
- University of Lorraine, Endocrinology, Diabetology and Nutrition Department, Nancy University Hospital, Nancy, France
| | - Samuel Frey
- Nantes University, CHU de Nantes, Oncological, Digestive and Endocrine Surgery, Institut des Maladies de l'Appareil Digestif, 44093 Nantes, France
| | - Eugénie Koumakis
- Centre de Référence des Maladies Osseuses Rares, Institut de Rhumatologie, Hôpital Cochin, Inserm UMR 1163, Paris, France
| | - Carole Guérin
- Department of General, Endocrine and Metabolic Surgery, La Conception Hospital, Aix-Marseille University, Marseille, France
| | - Rachel Desailloud
- Endocrinology-Diabetology and Nutrition Department, Hôpital Sud Nord, CHU, 80054 Amiens, France
| | - Lionel Groussin
- Endocrinology Department, Hôpital Cochin, Inserm U1016, CNRS UMR 8104, Université Paris Cité, Paris, France.
| | - Bertrand Cariou
- Endocrinology, Metabolism and Nutrition Department, Nantes Université, CHU de Nantes, CNRS, Inserm, l'Institut du Thorax, 44000 Nantes, France; CHU de Nantes, Inserm, CIC 1413, l'Institut du Thorax, 44000 Nantes, France
| | - Bruno Vergès
- Endocrinology and Diabetology Department, CHU de Dijon, Inserm UMR 1231, University of Burgundy and Franche-Comté, Dijon, France
| | - Laurent Brunaud
- University of Lorraine. Visceral, Metabolic and Cancer Surgery, CHU de Nancy, Nancy, France
| | - Eric Mirallié
- Nantes University, CHU de Nantes, Oncological, Digestive and Endocrine Surgery, Institut des Maladies de l'Appareil Digestif, 44093 Nantes, France
| | - Lucile Figueres
- Institut de Transplantation Urologie Néphrologie (ITUN), CHU de Nantes, Nantes, France; Centre de Recherche en Transplantation et Immunologie UMR 1064, Inserm, Université de Nantes, 44093 Nantes, France
| | - Hélène Lasolle
- Hospices Civils de Lyon, Groupement Hospitalier Est, Endocrinology Federation, Lyon, France
| |
Collapse
|
2
|
Frey S, Mosbah H, Donatini G, Brunaud L, Chabre O, Vezzosi D. Chapter 9: Indications for the treatment of primary hyperparathyroidism. ANNALES D'ENDOCRINOLOGIE 2025; 86:101698. [PMID: 39818285 DOI: 10.1016/j.ando.2025.101698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/18/2025]
Abstract
The choice of therapeutic method for the management of primary hyperparathyroidism depends on the severity of the disease and its complications at the time of diagnosis, the specific situation of each patient and his/her natural history, and assessment of the risk/benefit ratio for each method (surgery, local destruction or drugs). This chapter summarizes the indications for the treatment of primary hyperparathyroidism, based on the international literature available as of December 31st, 2023.
Collapse
Affiliation(s)
- Samuel Frey
- Institut du thorax, chirurgie cancérologique, digestive et endocrinienne, institut des maladies de l'appareil digestif, CNRS, Inserm, CHU de Nantes, Nantes université, 44000 Nantes, France
| | - Helena Mosbah
- Endocrinology, Diabetology and Nutrition Department, CHU de Poitiers, Inserm, ECEVE UMR 1123, université Paris-Cité, Paris, France
| | - Gianluca Donatini
- General and Endocrine Surgery Department, Inserm U1313-IRMETIST, CHU de Poitiers, Poitiers, France
| | - Laurent Brunaud
- Département de chirurgie viscérale, métabolique et cancérologique (CVMC), CHRU de Nancy, Inserm U1256 NGERE, université de Lorraine, Nancy, France
| | - Olivier Chabre
- Department of Endocrinology, CHU de Grenoble-Alpes, University of Grenoble-Alpes, Inserm-CEA-UGA UMR1292, 38043 Grenoble, France
| | - Delphine Vezzosi
- Endocrinology, Diabetology and Nutrition Department, CHU Larrey, 24, chemin de Pouvourville, TSA 30030, 31059 Toulouse, France.
| |
Collapse
|
3
|
Frey S, Gérard M, Guillot P, Wargny M, Bach-Ngohou K, Bigot-Corbel E, Renaud Moreau N, Caillard C, Mirallié E, Cariou B, Blanchard C. Parathyroidectomy Improves Bone Density in Women With Primary Hyperparathyroidism and Preoperative Osteopenia. J Clin Endocrinol Metab 2024; 109:1494-1504. [PMID: 38152848 DOI: 10.1210/clinem/dgad718] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Indexed: 12/29/2023]
Abstract
CONTEXT Osteoporosis and/or bone fractures are indications of parathyroidectomy in primary hyperparathyroidism (PHPT), especially in women. However, the benefit of surgery in patients with osteopenia remains unclear. OBJECTIVE To evaluate bone mineral density (BMD) and bone remodeling biomarkers changes 1 year after parathyroidectomy in women with PHPT. DESIGN In the prospective, monocentric, observational prospective cohort with primary hyperparathyroidism patients (CoHPT) cohort, women operated for sporadic PHPT since 2016 with ≥1 year follow-up were included. BMD (dual-X ray absorptiometry) and bone remodeling biomarkers [cross-linked C-telopeptide (CTX), procollagen type 1 N-terminal propeptide (P1NP), and bone-specific alkaline phosphatases] were assessed before and 1 year after parathyroidectomy. SETTING Referral center. PATIENTS A total of 177 women with PHPT (62.5 ± 13.3 years, 83.1% menopausal, 43.9% osteopenic, and 45.1% osteoporotic) were included. INTERVENTION Parathyroidectomy. MAIN OUTCOME MEASURE BMD change between before and 1 year after parathyroidectomy. RESULTS Parathyroidectomy resulted in significant increase in BMD and decrease in serum bone remodeling biomarker concentrations. In the 72 patients with baseline osteopenia, mean BMD significantly increased at the lumbar spine [+0.05 g/cm2 (95% confidence interval [CI], 0.03-0.07)], the femoral neck [+0.02 g/cm2 (95% CI 0.00-0.04)], the total hip [+0.02 g/cm2 (95% CI 0.01-0.02)], and the forearm [+0.01 (95% CI 0.00-0.02)], comparable to osteoporotic patients. Among osteopenic patients, those with individual BMD gain (>0.03 g/cm2) at ≥1 site had higher preoperative serum CTX, P1NP, and urine calcium concentrations than those without improvement. CONCLUSION Parathyroidectomy significantly improved BMD and remodeling biomarkers in women with osteopenia, thereby supporting the benefit of parathyroidectomy in these patients. Preoperative serum CTX and P1NP concentrations could be useful to predict expected BMD gain.
Collapse
Affiliation(s)
- Samuel Frey
- Nantes Université, CHU Nantes, Chirurgie Cancérologique, Digestive et Endocrinienne, Institut des Maladies de l'Appareil Digestif, F-44000 Nantes, France
- Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France
| | - Maxime Gérard
- Nantes Université, CHU Nantes, Chirurgie Cancérologique, Digestive et Endocrinienne, Institut des Maladies de l'Appareil Digestif, F-44000 Nantes, France
| | - Pascale Guillot
- Nantes Université, CHU Nantes, Service de Rhumatologie, F-44000 Nantes, France
| | - Matthieu Wargny
- Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France
- Nantes Université, CHU Nantes, Pôle Hospitalo-Universitaire 11: Santé Publique, Clinique des données, INSERM, CIC 1413, F-44000 Nantes, France
| | - Kalyane Bach-Ngohou
- Nantes Université, CHU Nantes, Department of Biochemistry and INSERM, The Enteric Nervous System in Gut and Brain Disorders, IMAD, F-4400 Nantes, France
| | - Edith Bigot-Corbel
- Nantes Université, CHU Nantes, Laboratoire de biochimie, Hôpital Guillaume et René Laennec, F-4400 Nantes, France
| | - Nelly Renaud Moreau
- Nantes Université, CHU Nantes, Chirurgie Cancérologique, Digestive et Endocrinienne, Institut des Maladies de l'Appareil Digestif, F-44000 Nantes, France
| | - Cécile Caillard
- Nantes Université, CHU Nantes, Chirurgie Cancérologique, Digestive et Endocrinienne, Institut des Maladies de l'Appareil Digestif, F-44000 Nantes, France
| | - Eric Mirallié
- Nantes Université, CHU Nantes, Chirurgie Cancérologique, Digestive et Endocrinienne, Institut des Maladies de l'Appareil Digestif, F-44000 Nantes, France
| | - Bertrand Cariou
- Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France
| | - Claire Blanchard
- Nantes Université, CHU Nantes, Chirurgie Cancérologique, Digestive et Endocrinienne, Institut des Maladies de l'Appareil Digestif, F-44000 Nantes, France
- Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France
| |
Collapse
|
4
|
Frey S, Guillot P, Wargny M, Gérard M, Bigot-Corbel E, Bach-Ngohou K, Caillard C, Cariou B, Mirallié E, Blanchard C. Do men improve their bone mineral density 1 year after parathyroidectomy for primary hyperparathyroidism? Results of a prospective study. Surgery 2024; 175:172-179. [PMID: 37935599 DOI: 10.1016/j.surg.2023.04.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2023] [Revised: 04/09/2023] [Accepted: 04/27/2023] [Indexed: 11/09/2023]
Abstract
BACKGROUND The impact of parathyroidectomy on bone mineral density in men with primary hyperparathyroidism is poorly known. This study aimed to evaluate the bone mineral density and bone remodeling biomarker changes in men with primary hyperparathyroidism 1 year after parathyroidectomy. METHODS Men operated for sporadic primary hyperparathyroidism between 2016 and 2022, enrolled in a monocentric prospective cohort, were analyzed. Patients with follow-up <1 year or missing data were excluded. Bone mineral density (dual X-ray absorptiometry) was measured before and 12 months after parathyroidectomy. Bone mineral density change ≥0.03g/cm2 was deemed significant. Bone remodeling biomarkers were serum cross-linked C-telopeptide, procollagen type 1 N-terminal propeptide, and bone-specific alkaline phosphatases. RESULTS Forty-five men were included (mean age 58.8 ± 13.1 years). Before surgery, 49% had osteopenia, and 11% had osteoporosis. Mean serum calcium and median serum parathyroid hormone levels decreased significantly after surgery (P < .0001). One year after parathyroidectomy, the mean bone mineral density increased significantly at the lumbar spine (+0.04g/cm2 [0.01;0.70], P = .0054), femoral neck (+0.04g/cm2 [0.03;0.05], P < .0001) and total hip (+0.02g/cm2 [0.01;0.03], P = .0002). Considering significant bone mineral density gain (+1 point) and loss (-1 point) at each site, 29/45 patients (64% [95% CI 49;78]) improved. Bone remodeling biomarker concentrations significantly decreased (P < .001). CONCLUSION Parathyroidectomy positively affects bone mineral density in men with primary hyperparathyroidism, supporting osteopenia as a surgical indication in these patients.
Collapse
Affiliation(s)
- Samuel Frey
- Nantes Université, CHU Nantes, Chirurgie Cancérologique, Digestive et Endocrinienne, Institut des Maladies de l'Appareil Digestif, Nantes, France; Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, Nantes, France. https://twitter.com/samuelfrey13
| | - Pascale Guillot
- Nantes Université, CHU Nantes, Service de Rhumatologie, Nantes, France
| | - Matthieu Wargny
- Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, Nantes, France; Nantes Université, CHU Nantes, Pôle Hospitalo-Universitaire 11 : Santé Publique, Clinique des données, INSERM, CIC 1413, Nantes, France
| | - Maxime Gérard
- Nantes Université, CHU Nantes, Chirurgie Cancérologique, Digestive et Endocrinienne, Institut des Maladies de l'Appareil Digestif, Nantes, France
| | - Edith Bigot-Corbel
- Nantes Université, CHU Nantes, Laboratoire de biochimie, Hôpital Guillaume et René Laennec, Nantes, France
| | - Kalyane Bach-Ngohou
- Nantes Université, CHU Nantes, Department of Biochemistry and INSERM, The enteric nervous system in gut and brain disorders, IMAD, F-4400 Nantes, France
| | - Cécile Caillard
- Nantes Université, CHU Nantes, Chirurgie Cancérologique, Digestive et Endocrinienne, Institut des Maladies de l'Appareil Digestif, Nantes, France
| | - Bertrand Cariou
- Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, Nantes, France
| | - Eric Mirallié
- Nantes Université, CHU Nantes, Chirurgie Cancérologique, Digestive et Endocrinienne, Institut des Maladies de l'Appareil Digestif, Nantes, France
| | - Claire Blanchard
- Nantes Université, CHU Nantes, Chirurgie Cancérologique, Digestive et Endocrinienne, Institut des Maladies de l'Appareil Digestif, Nantes, France; Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, Nantes, France.
| |
Collapse
|